DOSAGE INDEX / SINGLE
Survodutide
Research, reported schedules and supply planning.
Explore survodutide obesity and liver trials, primary versus adherence-assuming weight results, treatment discontinuations and current research status.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 0.6–6 mg per week
- Frequency
- Once weekly
- Cycle / observation period
- 12–16 weeks in its overview; trial durations differ
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- The dose-finding trial randomized 387 adults without diabetes; 386 received treatment. At 46 weeks, the planned-treatment analysis estimated weight changes from -6.2% to -14.9% across survodutide arms, versus -2.8% with placebo. Only 233 treated participants completed the treatment period. Gastrointestinal adverse events occurred in 75% of survodutide recipients and 42% of placebo recipients. [1]
- The SYNCHRONIZE-1 safety table reported adverse events leading to discontinuation of the study intervention in 23.7% and 24.8% of the survodutide groups, versus 5.4% with placebo. Serious adverse events occurred in 8.3%, 8.3% and 6.2%, respectively. [2]
- Nausea, diarrhea and vomiting were more frequent with survodutide than placebo in that study; serious adverse events were reported in 8% versus 7%. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 13 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original phase 2 obesity trial
- Original phase 3 publication
- MASH trial safety findings
- Journal of Hepatology (2023)Further reading · Listed in reference bibliography.
- Obesity (Silver Spring) (2024)Further reading · Listed in reference bibliography.
- JACC: Heart Failure (2024)Further reading · Listed in reference bibliography.
- Diabetology & Metabolic Syndrome (2024)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- MedlinePlus (NIH)General guidance · Listed in reference bibliography.
- Veterans Affairs (2023)Further reading · Listed in reference bibliography.
- Nature Reviews Endocrinology (2023)No destination link supplied in the source bibliography.Further reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.